Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nestle Group
Nestle Group
Activities:
Active Nutrition
Food
Nutraceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Nestlé tackles phenylketonuria with Codexis enzyme
Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisation of the orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU)
Ingredients
Nestlé agrees joint venture with China MediTech
NSP will develop nutritional and medical products derived from botanical plants
Finance
Nestlé Health Science to buy Prometheus Laboratories
Makes a strategic move into gastrointestinal diagnostics
Finance
Novartis and Alcon agree merger terms
Will create a new eyecare group with Ciba Vision and ophthalmic medicines business
Novartis to buy rest of Alcon
<p>Swiss pharmaceutical group Novartis is to purchase 52% of eye care specialist Alcon from Nestle in the second stage of a US$38.5bn deal agreed in 2008.</p>
Media
Alcon to acquire ESBATech
<p>Eye care specialist Alcon is to acquire Swiss biotechnology company ESBATech, based in Zurich, for US$150m in cash.</p>
Subscribe now